A clinical trial including 35 ccRCC patients treated with cG250 associated with a low dose of IL2 for 11 weeks presented durable response in 23% of the patients, with several grade 3 or 4 toxicities [31]. This evidence concerns the gene IL2 and nonpapillary renal cell carcinoma.